Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA).
blastomyces
coccidioides
histoplasma
paracoccidioides
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
18
07
2022
received:
21
04
2022
accepted:
24
07
2022
pubmed:
17
8
2022
medline:
8
11
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
The Americas are home to biologically and clinically diverse endemic fungi, including Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides and Sporothrix. In endemic areas with high risk of infection, these fungal pathogens represent an important public health problem. This report aims to summarise the main findings of the regional analysis carried out on the status of the endemic mycoses of the Americas, done at the first International Meeting on Endemic Mycoses of the Americas (IMEMA). A regional analysis for the Americas was done, the 27 territories were grouped into nine regions. A SWOT analysis was done. All territories reported availability of microscopy. Seventy percent of territories reported antibody testing, 67% of territories reported availability of Histoplasma antigen testing. None of the territories reported the use of (1-3)-β-d-glucan. Fifty two percent of territories reported the availability of PCR testing in reference centres (mostly for histoplasmosis). Most of the territories reported access to medications such as trimethoprim-sulfamethoxazole, itraconazole, voriconazole and amphotericin B (AMB) deoxycholate. Many countries had limited access to liposomal formulation of AMB and newer azoles, such as posaconazole and isavuconazole. Surveillance of these fungal diseases was minimal. A consensus emerged among meeting participants, this group concluded that endemic mycoses are neglected diseases, and due to their severity and lack of resources, the improvement of diagnosis, treatment and surveillance is needed.
Sections du résumé
BACKGROUND
BACKGROUND
The Americas are home to biologically and clinically diverse endemic fungi, including Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides and Sporothrix. In endemic areas with high risk of infection, these fungal pathogens represent an important public health problem.
OBJECTIVES
OBJECTIVE
This report aims to summarise the main findings of the regional analysis carried out on the status of the endemic mycoses of the Americas, done at the first International Meeting on Endemic Mycoses of the Americas (IMEMA).
METHODS
METHODS
A regional analysis for the Americas was done, the 27 territories were grouped into nine regions. A SWOT analysis was done.
RESULTS
RESULTS
All territories reported availability of microscopy. Seventy percent of territories reported antibody testing, 67% of territories reported availability of Histoplasma antigen testing. None of the territories reported the use of (1-3)-β-d-glucan. Fifty two percent of territories reported the availability of PCR testing in reference centres (mostly for histoplasmosis). Most of the territories reported access to medications such as trimethoprim-sulfamethoxazole, itraconazole, voriconazole and amphotericin B (AMB) deoxycholate. Many countries had limited access to liposomal formulation of AMB and newer azoles, such as posaconazole and isavuconazole. Surveillance of these fungal diseases was minimal.
CONCLUSIONS
CONCLUSIONS
A consensus emerged among meeting participants, this group concluded that endemic mycoses are neglected diseases, and due to their severity and lack of resources, the improvement of diagnosis, treatment and surveillance is needed.
Identifiants
pubmed: 35971917
doi: 10.1111/myc.13510
pmc: PMC9804294
doi:
Substances chimiques
Antifungal Agents
0
Itraconazole
304NUG5GF4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1179-1187Informations de copyright
© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
Open Forum Infect Dis. 2019 Apr 13;6(4):ofz073
pubmed: 30997365
Curr Opin Microbiol. 2019 Dec;52:55-63
pubmed: 31181385
Mycoses. 2021 Dec;64(12):1563-1570
pubmed: 34536307
AIDS. 2020 Sep 1;34(11):1625-1632
pubmed: 32694415
Mycopathologia. 2020 Oct;185(5):843-865
pubmed: 32040709
Microorganisms. 2021 Dec 16;9(12):
pubmed: 34946197
Lancet Infect Dis. 2017 Nov;17(11):e367-e377
pubmed: 28774696
Mycoses. 2019 Jun;62(6):502-507
pubmed: 30734964
Mycoses. 2022 Mar;65(3):354-361
pubmed: 34936142
Mycoses. 2021 Nov;64(11):1396-1401
pubmed: 33966300
Am J Trop Med Hyg. 2015 Sep;93(3):662-7
pubmed: 26123961
Mycoses. 2019 Apr;62(4):368-373
pubmed: 30614600
Mycoses. 2021 Sep;64(9):989-992
pubmed: 34036653
J Fungi (Basel). 2021 Feb 20;7(2):
pubmed: 33672469
Mycoses. 2022 Dec;65(12):1179-1187
pubmed: 35971917